BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 36200323)

  • 21. Dose-specific Effectiveness of 7- and 13-Valent Pneumococcal Conjugate Vaccines Against Vaccine-serotype Streptococcus pneumoniae Colonization in Children.
    Lewnard JA; Givon-Lavi N; Dagan R
    Clin Infect Dis; 2020 Nov; 71(8):e289-e300. PubMed ID: 31784753
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of introducing the pneumococcal conjugate vaccine for children under 5 years in the Islamic Republic of Iran.
    Ezoji K; Yaghoubi M; Nojomi M; Mahmoody S; Zahraie SM; Moradi-Lakeh M; Tabatabaei SR; Karimi A
    East Mediterr Health J; 2019 Nov; 25(10):686-697. PubMed ID: 31774134
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Parents' attitudes, knowledge and practice towards vaccinating their children against COVID-19: a cross-sectional study.
    Al-Qerem W; Al Bawab AQ; Hammad A; Jaber T; Khdair SI; Kalloush H; Ling J; Mosleh R
    Hum Vaccin Immunother; 2022 Nov; 18(5):2044257. PubMed ID: 35240943
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of reduced-dose schedules with 7-valent pneumococcal conjugate vaccine on nasopharyngeal pneumococcal carriage in children: a randomized controlled trial.
    van Gils EJ; Veenhoven RH; Hak E; Rodenburg GD; Bogaert D; Ijzerman EP; Bruin JP; van Alphen L; Sanders EA
    JAMA; 2009 Jul; 302(2):159-67. PubMed ID: 19584345
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness analysis of the introduction of the pneumococcal conjugate vaccine (PCV-13) in the Egyptian national immunization program, 2013.
    Sibak M; Moussa I; El-Tantawy N; Badr S; Chaudhri I; Allam E; Baxter L; Abo Freikha S; Hoestlandt C; Lara C; Hajjeh R; Munier A
    Vaccine; 2015 May; 33 Suppl 1():A182-91. PubMed ID: 25919159
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modeling the impact of the 7-valent pneumococcal conjugate vaccine in Chinese infants: an economic analysis of a compulsory vaccination.
    Che D; Zhou H; He J; Wu B
    BMC Health Serv Res; 2014 Feb; 14():56. PubMed ID: 24507480
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recent advances in pneumococcal vaccination of children.
    Russell FM; Mulholland EK
    Ann Trop Paediatr; 2004 Dec; 24(4):283-94. PubMed ID: 15720885
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pneumococcal vaccine uptake among high-risk adults and children in Italy: results from the OBVIOUS project survey.
    Di Valerio Z; La Fauci G; Scognamiglio F; Salussolia A; Montalti M; Capodici A; Fantini MP; Odone A; Costantino C; Soldà G; Larson HJ; Leask J; Lenzi J; Gori D;
    BMC Public Health; 2024 Mar; 24(1):736. PubMed ID: 38454392
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness and Health Benefits of Pediatric 23-valent Pneumococcal Polysaccharide Vaccine, 7-valent Pneumococcal Conjugate Vaccine and Forecasting 13-valent Pneumococcal Conjugate Vaccine in China.
    Mo X; Gai Tobe R; Liu X; Mori R
    Pediatr Infect Dis J; 2016 Nov; 35(11):e353-e361. PubMed ID: 27753771
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness of Pneumococcal Conjugate Vaccines (PCV7 and PCV13) against Invasive Pneumococcal Disease among Children under Two Years of Age in Germany.
    van der Linden M; Falkenhorst G; Perniciaro S; Fitzner C; Imöhl M
    PLoS One; 2016; 11(8):e0161257. PubMed ID: 27526117
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness of a 2+1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway.
    Vestrheim DF; Løvoll O; Aaberge IS; Caugant DA; Høiby EA; Bakke H; Bergsaker MR
    Vaccine; 2008 Jun; 26(26):3277-81. PubMed ID: 18456376
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Public health impact of pneumococcal conjugate vaccine infant immunization programs: assessment of invasive pneumococcal disease burden and serotype distribution.
    Izurieta P; Bahety P; Adegbola R; Clarke C; Hoet B
    Expert Rev Vaccines; 2018 Jun; 17(6):479-493. PubMed ID: 29241390
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pneumococcal conjugate vaccines for preventing acute otitis media in children.
    Fortanier AC; Venekamp RP; Boonacker CW; Hak E; Schilder AG; Sanders EA; Damoiseaux RA
    Cochrane Database Syst Rev; 2019 May; 5(5):CD001480. PubMed ID: 31135969
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of age and vaccination with a pneumococcal conjugate vaccine on the density of pneumococcal nasopharyngeal carriage.
    Roca A; Bottomley C; Hill PC; Bojang A; Egere U; Antonio M; Darboe O; Greenwood BM; Adegbola RA
    Clin Infect Dis; 2012 Sep; 55(6):816-24. PubMed ID: 22700830
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness of pneumococcal conjugate vaccination in Croatia.
    Vučina VV; Filipović SK; Kožnjak N; Stamenić V; Clark AD; Mounaud B; Blau J; Hoestlandt C; Kaić B
    Vaccine; 2015 May; 33 Suppl 1():A209-18. PubMed ID: 25919163
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness analysis of infant pneumococcal vaccination with PHiD-CV in Korea.
    Zhang XH; Leeuwenkamp O; Oh KB; Lee YE; Kim CM
    Hum Vaccin Immunother; 2018 Jan; 14(1):85-94. PubMed ID: 29115905
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Provider adoption of pneumococcal conjugate vaccine and the impact of vaccine shortages.
    Daley MF; Crane LA; Beaty BL; Barrow J; Pearson K; Stevenson JM; Berman S; Kempe A
    Ambul Pediatr; 2005; 5(3):157-64. PubMed ID: 15913409
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early Declines in Vaccine Type Pneumococcal Carriage in Children Less Than 5 Years Old After Introduction of 10-valent Pneumococcal Conjugate Vaccine in Mozambique.
    Sigaúque B; Moiane B; Massora S; Pimenta F; Verani JR; Mucavele H; Chaúque A; Quintó L; Dos Santos RT; Carvalho MDG; Whitney CG; Lessa FC
    Pediatr Infect Dis J; 2018 Oct; 37(10):1054-1060. PubMed ID: 30216295
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of the 13-valent pneumococcal conjugate vaccine in children and adolescents aged 6 - 17 years.
    Mitchell R; Trück J; Pollard AJ
    Expert Opin Biol Ther; 2013 Oct; 13(10):1451-65. PubMed ID: 23889554
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Early impact of pneumococcal conjugate vaccine on invasive pneumococcal disease in Singapore children, 2005 through 2010.
    Thoon KC; Chong CY; Tee NW
    Int J Infect Dis; 2012 Mar; 16(3):e209-15. PubMed ID: 22281191
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.